BOULDER, Colo. — BioMed Realty announced that CordenPharma Colorado has signed a 15-year lease for a newly completed 64,000-square-foot laboratory building at Flatiron Park, expanding the contract development and manufacturing organization’s peptide drug development capabilities in Boulder.
CordenPharma Colorado will be the sole tenant at 5505 Central, a purpose-built laboratory facility and the first speculative lab building constructed at the Flatiron Park campus. The site is located near the company’s existing peptide manufacturing facility, allowing closer integration between early-stage development work and large-scale production.
The new LEED Gold-certified building includes high-capacity power systems, adaptable laboratory layouts, advanced mechanical and utility infrastructure, and specialized waste management capabilities designed to support complex scientific operations. The space will house process development and analytical services supporting peptide active pharmaceutical ingredient development from early research through commercial manufacturing.
BioMed Realty said the lease reinforces Flatiron Park’s role as a major hub for life science, technology, and innovation companies in Boulder. The campus provides infrastructure and flexible laboratory environments designed to support growing research organizations.
“We’re proud to deliver the first purpose-built lab building at Flatiron Park, designed to meet the flexibility and performance needs of sophisticated science users,” said Jon Bergschneider, President, West Coast Markets at BioMed Realty. “Combined with a connected campus experience, curated amenities, Discover Here programming, and a tenant-first operating model, Flatiron Park supports innovation today while enabling long-term growth.”
The expansion is expected to support CordenPharma’s growing peptide development operations and strengthen its global network of facilities across the United States and Europe.
“We’re excited to partner with BioMed Realty on this project to accelerate our strategic growth and meet customer demand for complex peptide outsourcing, while creating additional jobs and attracting research talent to the region,” said Michael Landau, Managing Director of CordenPharma Colorado. “With our strong team and strategic vision, backed by our global facility network, these new labs will grow the life sciences sector in Boulder. As a CDMO, our Development Laboratories are foundational in delivering effective support to customers and their patients.”
Jennifer Chavez, Senior Director of Leasing at BioMed Realty, said the lease highlights the company’s continued investment in the region’s research ecosystem.
“The addition of CordenPharma to Flatiron Park reflects the vital role BioMed Realty plays in supporting Boulder’s innovation ecosystem,” Chavez said. “We provide the high-quality, reliable infrastructure and adaptable environments leading companies like CordenPharma need to succeed.”
